Editing DPT vaccine (section)

{{Short description|Combination vaccine}}
{{Other uses|DPT (disambiguation)}}
{{redirect|TDAP|other uses|}}
{{Use dmy dates|date=March 2025}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 476997263
| type = combo
| image = Global vaccination coverage- Diphtheria-tetanus-pertussis (DTP3) immunization, OWID.svg
| caption = Global vaccination coverage- diphtheria-tetanus-pertussis (DTP3) immunization<ref>{{cite web |title=Global vaccination coverage: Diphtheria-tetanus-pertussis (DTP3) immunization |url=https://ourworldindata.org/grapher/diphtheria-tetanus-pertussis-dtp3-immunization-global |website=Our World in Data |access-date=5 March 2020 |archive-date=21 April 2020 |archive-url=https://web.archive.org/web/20200421144130/https://ourworldindata.org/grapher/diphtheria-tetanus-pertussis-dtp3-immunization-global |url-status=dead }}</ref>

<!-- Vaccine data -->
| component1 = Diphtheria vaccine
| class1 = [[Vaccine]]
| component2 = Pertussis vaccine
| class2 = [[Vaccine]]
| component3 = Tetanus vaccine
| class3 = [[Vaccine]]

<!-- Clinical data -->
| tradename = Adacel, Boostrix, Revaxis, others
| Drugs.com = {{drugs.com|uk|revaxis-suspension-for-injection-in-pre-filled-syringe-leaflet}}
| MedlinePlus =
| licence_CA =
| licence_EU =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category =
| routes_of_administration = [[Intramuscular]] injection
| ATC_prefix = None
| ATC_suffix =

| legal_AU = S4
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_US_comment = <ref>{{cite web | title=Boostrix-IPV 0.5 mL injection syringe (96137) | website=Therapeutic Goods Administration (TGA) | date=26 May 2022 | url=https://www.tga.gov.au/resources/artg/96137 | access-date=24 March 2025}}</ref><ref>{{cite web | title=Boostrix-IPV (GlaxoSmithKline Australia Pty Ltd) | website=Therapeutic Goods Administration (TGA) | date=13 March 2025 | url=https://www.tga.gov.au/resources/prescription-medicines-registrations/boostrix-ipv-glaxosmithkline-australia-pty-ltd | access-date=24 March 2025}}</ref><ref>{{cite web | title=Boostrix 0.5 mL injection pre-filled syringe (158363) | website=Therapeutic Goods Administration (TGA) | date=26 May 2022 | url=https://www.tga.gov.au/resources/artg/158363 | access-date=24 March 2025}}</ref> with standing order<ref>{{cite web |title=standing orders for Administering Diphtheria, Tetanus, and Acellular Pertussis (DTaP)Vaccine to Children YoungerThan Age 7Years |url=https://www.immunize.org/wp-content/uploads/catg.d/p3073.pdf |website=immunize.org |access-date=4 July 2024 |archive-date=26 February 2024 |archive-url=https://web.archive.org/web/20240226015942/https://www.immunize.org/wp-content/uploads/catg.d/p3073.pdf |url-status=live }}</ref><ref>{{cite web |title=standing orders for Administering Tdap/Td Vaccine to Children and Teens Age 7 Years and Older |url=https://www.immunize.org/wp-content/uploads/catg.d/p3078a.pdf |website=immunize.org |access-date=4 July 2024 |archive-date=10 June 2024 |archive-url=https://web.archive.org/web/20240610005633/https://www.immunize.org/wp-content/uploads/catg.d/p3078a.pdf |url-status=live }}</ref><ref>{{cite web |title=standing orders for Administering Td/Tdap Vaccine to Adults |url=https://www.immunize.org/wp-content/uploads/catg.d/p3078.pdf |website=immunize.org |access-date=4 July 2024 |archive-date=26 February 2024 |archive-url=https://web.archive.org/web/20240226183952/https://www.immunize.org/wp-content/uploads/catg.d/p3078.pdf |url-status=live }}</ref><ref>{{cite web |title=standing orders for Administering Tdap During Pregnancy |url=https://www.immunize.org/wp-content/uploads/catg.d/p3078b.pdf |website=immunize.org |access-date=4 July 2024 |archive-date=19 May 2024 |archive-url=https://web.archive.org/web/20240519115539/https://www.immunize.org/wp-content/uploads/catg.d/p3078b.pdf |url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref>{{cite web |title=List of nationally authorised medicinal products |url=https://www.ema.europa.eu/en/documents/psusa/diphtheriatetanuspertussis-acellular-component-vaccine-adsorbed-diphtheriatetanuspertussis-acellular-component-vaccine-adsorbed-reduced-antigens-contents-list-nationally-authorised-medicinal-pr_en.pdf |website=ema.europa.eu |access-date=4 July 2024}}</ref>
| legal_status = Rx-only

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 863488-19-1
| PubChem =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| KEGG = D05356
}}

The '''DPT vaccine''' or '''DTP vaccine''' is a class of combination [[vaccine]]s to protect 
against three [[infectious disease]]s in humans: [[diphtheria]], [[pertussis]] (whooping cough), and [[tetanus]] (lockjaw).<ref name="DTaP VIS">{{cite web | title=DTaP (Diphtheria, Tetanus, Pertussis) Vaccine Information Statement | website=U.S. [[Centers for Disease Control and Prevention]] (CDC) | url=https://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html | date=1 April 2020 | access-date=27 July 2020 | archive-date=28 December 2019 | archive-url=https://web.archive.org/web/20191228060050/https://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html | url-status=live }} {{PD-notice}}</ref> The vaccine components include diphtheria and tetanus [[toxoids]], and either killed whole cells of the [[bacterium]] that causes pertussis or pertussis [[antigens]]. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself.<ref>{{cite web |date=26 April 2021 |title=Vaccine Types |url=https://www.hhs.gov/immunization/basics/types/index.html |access-date=19 September 2022 |website=HHS |archive-date=16 July 2021 |archive-url=https://web.archive.org/web/20210716125750/https://www.hhs.gov/immunization/basics/types/index.html |url-status=live }}</ref> The whole cells or [[antigen]]s will be depicted as either "DTwP"<ref name=iran-choice/> or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular".<ref name=MMWR18>{{cite journal | vauthors = Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA | title = Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) | journal = MMWR. Recommendations and Reports | volume = 67 | issue = 2 | pages = 1–44 | date = April 2018 | pmid = 29702631 | pmc = 5919600 | doi = 10.15585/mmwr.rr6702a1 }} {{PD-notice}}</ref> In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid (and for pertussis, either a dead pathogen or pure antigens) to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.<ref>{{cite web |title=Understanding Six Types of Vaccine Technologies |url=https://www.pfizer.com/news/articles/understanding_six_types_of_vaccine_technologies |access-date=19 September 2022 |website=Pfizer |archive-date=20 September 2022 |archive-url=https://web.archive.org/web/20220920172734/https://www.pfizer.com/news/articles/understanding_six_types_of_vaccine_technologies |url-status=live }}</ref>

In the United States, the DPT (whole-cell) vaccine was administered as part of the childhood vaccines recommended by the [[Centers for Disease Control and Prevention]] (CDC) until 1996, when the acellular DTaP vaccine was licensed for use.<ref name=":2">{{cite web|year=2020|title=Birth-18 Years Immunization Schedule|url=https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html|access-date=30 July 2020|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|archive-date=6 March 2016|archive-url=https://web.archive.org/web/20160306220930/http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html|url-status=live}}</ref>

{{hatnote|Unless otherwise noted, this article uses "DPT" and "DTP" to refer to any combination vaccine that targets diphtheria, tetanus, and pertussis. The whole-cell vaccine is mentioned either as DTwP or as its historical name (DPT/DTP) with parenthetical remarks.}}